Prelude Therapeutics Incorporated
PRLD
$1.27
$0.032.42%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 10.10% | -2.08% | 13.13% | -5.43% | -14.16% |
| Total Depreciation and Amortization | -4.20% | 2.11% | 47.73% | 45.16% | 60.85% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -22.84% | -2.83% | -41.07% | -1.24% | -24.25% |
| Change in Net Operating Assets | -87.82% | -32.08% | 15.33% | -0.76% | 240.01% |
| Cash from Operations | -13.09% | -7.68% | 12.02% | -6.28% | 16.67% |
| Capital Expenditure | 94.43% | 83.74% | 95.31% | 89.34% | 63.48% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -56.41% | 97.50% | 150.10% | -30.95% | 135.57% |
| Cash from Investing | -55.89% | 99.18% | 185.91% | -28.66% | 134.63% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 44.79% | -- | -- | -- | -- |
| Issuance of Common Stock | -64.20% | -- | -99.51% | -46.15% | -99.77% |
| Repurchase of Common Stock | 88.89% | 68.75% | -600.00% | 18.75% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -128.28% |
| Cash from Financing | -37.29% | -1,042.86% | -100.13% | -248.86% | -99.95% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -565.14% | 4,859.42% | -85.74% | -58.24% | -62.15% |